Significant support from investors including the European Investment Fund Fund to invest in first and best-in-class European life science companies in drug development and digital health Luxembourg-Strassen, 29 June 2023 – Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of […]
Professor Dmochowski is a world leading key opinion leader in female urology and urologic reconstruction Versameb is accelerating preparations for IND filing of lead candidate VMB-100 Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer […]
Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Read more…
Leading industry expert with more than 25 years of experience in translation research in immunology Basel, Switzerland, 23 May 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D’Andrea to its board of directors as a non-executive director as of […]
Clinical candidate selection finalised for lead programme targeting mast-cell driven diseases Dermatology industry veteran Thibaud Portal, PhD appointed as CEO London, UK, March 30, 2023 – Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which […]
